Eligibility criteria:
The included studies were chosen on the basis of the following criteria:
study population, intervention, comparison, outcomes of interest, study
design, and definition.
- Patient population: adults (aged ≥18 years) with type 2 diabetes and
CKD
- Exposure: Maximum tolerated labelled dose of an angiotensin-converting
enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB).
- Comparison: This includes the non-finerenone group which received the
usual standard of care or placebo.
- Outcomes of interest: Efficacy and adverse effects of Finerenone
- Study design: Eligible completed randomized clinical trials were
extracted to perform the meta-analysis.
Observational studies, case reports, and reviews were excluded from the
meta-analysis at screening. Additionally, studies with non-human
participants, children <18 years, or pregnant women were not
included for analysis.